✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Depo-Provera settlement administration orders: what claimants should track now

Last reviewed: September 16, 2026

The Depo-Provera meningioma MDL has moved into a more practical stage. The newest court orders are not about a public payout chart. They are about who will help run the settlement program, who will review records, who will handle settlement funds, who will deal with medical liens, and who may review requests for extra compensation.

That matters for women who used Depo-Provera or a related depot medroxyprogesterone acetate product and were later diagnosed with an intracranial meningioma. A settlement process, when it applies, usually turns on documentation. It does not run on rumors, screenshots, or guesses about a dollar amount.

Our main Depo-Provera lawsuit page explains the core allegations in MDL 3140. This update is narrower. It explains the September 2026 administration orders and the claimant-facing issues they point to.

What the September orders added

The federal Depo-Provera cases are centralized in the Northern District of Florida as MDL No. 3140 before Judge M. Casey Rodgers. The court's MDL page says the cases share allegations that injectable Depo-Provera or generic equivalents can cause users to develop one or more meningiomas, while defendants maintain the medication is safe and effective.

On September 4, 2026, the court posted three new case management orders tied to settlement administration:

Case Management Order No. 15 appoints Matt Garretson of Garretson, LLC as Supplemental Compensation Fund Allocation Master.
Case Management Order No. 16 appoints Randall Sansom CPA as Qualified Settlement Fund Administrator.
Case Management Order No. 17 appoints BrownGreer PLC as Lien Resolution Administrator.

These orders followed the August 5 order appointing BrownGreer PLC as Settlement Administrator. Together, they show that the court is building the machinery needed to review eligibility, handle documentation, administer funds, address liens, and report progress back to the court.

They do not publish final individual payment amounts. They also do not say that every person with a meningioma claim is automatically included.

The settlement administrator reviews eligibility and records

Case Management Order No. 13 appoints BrownGreer as Settlement Administrator. The order says BrownGreer will coordinate settlement program design, allocation methodology, and documentation requirements. It also says BrownGreer will use information collected from individuals and their counsel to perform eligibility determinations and will review submissions and supporting records.

For claimants, that is the key takeaway. The review is record-based. A person may remember years of Depo-Provera injections, but the settlement administrator generally needs documents that prove exposure and diagnosis.

Helpful records may include:

injection records from an OB/GYN, health department, family planning clinic, primary care office, or college clinic;
pharmacy benefit records or insurance explanation-of-benefits records showing DMPA, Depo-Provera, Depo-SubQ Provera 104, or an authorized generic;
MRI or CT reports identifying a meningioma;
neurology, neurosurgery, radiation oncology, operative, or pathology records; and
follow-up records showing symptoms, treatment, monitoring, or work and daily-life limits.

If the clinic closed or the patient changed names, the records may still exist in a hospital system, old portal, insurer file, state immunization-style clinic record, or archived chart. The problem is often finding the right custodian, not proving the memory was wrong.

The Qualified Settlement Fund handles money after eligibility steps

Case Management Order No. 16 appoints Randall Sansom CPA as Qualified Settlement Fund Administrator. The order says the QSF administrator will act as fiduciary of the settlement trust, handle trust accounts and tax-related administration, coordinate with the settlement and lien administrators, and provide information necessary for payment of claims.

In plain English, the QSF role is about settlement funds after the program is ready to move money. It is not the same thing as deciding every medical issue in a claim. It also is not a public promise that a particular person will receive a specific amount by a specific date.

Claimants should be careful with online posts that skip over eligibility review and jump straight to predicted checks. The court orders describe administration roles. They do not publish a compensation grid.

Medical liens can affect what a claimant receives

Case Management Order No. 17 appoints BrownGreer as Lien Resolution Administrator. The order says the LRA will help claimants and their counsel identify and resolve liens against settlement awards relating to medical care, and it notes that costs and expenses for use of the LRA will be paid by settling claimants.

A lien is a claim that may have to be resolved out of a settlement because a health plan, government program, or provider paid for care connected to the injury. In a meningioma case, that may involve imaging, surgery, hospitalization, radiation, follow-up care, or other treatment.

This is one reason a gross settlement number, if one is ever discussed, is not the same as take-home compensation. Attorney fees, case costs, common-benefit assessments, liens, and individual facts can all matter. Anyone reviewing a claim should ask how liens will be checked and what documents may be needed.

The Supplemental Compensation Fund points to an extra-review process

Case Management Order No. 15 appoints Matt Garretson as Supplemental Compensation Fund Allocation Master. The order says the allocation master will administer the process by which an eligible claimant may seek additional compensation from the Supplemental Compensation Fund, including developing criteria for qualified petitions and applying those criteria to individual facts.

That language matters because it suggests the program may have a separate process for some eligible claimants seeking additional compensation. The order does not publish the criteria. It does say the decision will depend on facts of the claimant's case.

For potential claimants, this reinforces a practical point: the severity and documentation of the diagnosis may matter. Operative reports, pathology, tumor location, complications, repeat imaging, radiation records, seizure treatment, visual or hearing problems, and work restrictions may be more important than a short note saying "brain tumor."

Current case-count and court-status context

The August 3, 2026 JPML statistics report listed MDL 3140 with 6,294 actions pending and 6,394 historical actions. That makes Depo-Provera one of the larger active product-liability MDLs in the federal system.

The Northern District of Florida's MDL page also lists a September 18, 2026 case management conference and a Rule 702 motions hearing following the conference. Rule 702 is the federal expert-testimony rule. For claims that do not resolve through any settlement program, expert evidence and general-causation rulings may still affect the path forward.

This is why public updates can sound complicated. The case can have settlement administration moving for eligible claims while litigation issues remain important for claims that fall outside the program or still need court rulings.

What claimants should do now

Start with a clean timeline. Write down the approximate dates and locations of Depo-Provera, Depo-SubQ Provera 104, or generic DMPA injections. Then match each entry to a record source: clinic chart, billing record, pharmacy benefit entry, insurance claim, or patient portal.

Next, build the diagnosis timeline. Identify the first scan that showed the meningioma, the doctor who explained it, any surgery or radiation, pathology results, and follow-up imaging.

Finally, avoid medical decisions based on lawsuit news. Pfizer's current Depo-Provera prescribing information includes a meningioma warning and says Depo-Provera should be discontinued if a meningioma is diagnosed, but contraception and treatment decisions belong with a medical professional who knows the patient's health history.

Short FAQ

Do the September 2026 orders announce settlement amounts?

No. The orders appoint administrators and describe their roles. They do not publish individual payment amounts, a public settlement grid, or final eligibility rules.

Does a settlement administrator mean my claim is approved?

No. The August order says the settlement administrator will perform eligibility determinations and review supporting records. Approval depends on the program rules and the claimant's documents.

Why do liens matter in a Depo-Provera meningioma claim?

Medical liens may have to be resolved from a settlement award when a health plan, government program, or provider paid for care related to the claimed injury.

What records should I look for first?

Start with proof of DMPA injections and proof of meningioma diagnosis: clinic injection records, insurance or pharmacy records, MRI or CT reports, and operative or pathology records if surgery occurred.

Sources

Attorney Advertising. This article is for general information only. It is not medical advice or legal advice. Reading it or submitting a form does not create an attorney-client relationship. Every claim depends on the person's records, exposure history, deadlines, settlement criteria, and applicable law.

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →